Robert Strother

Robert Strother is a medical-device engineering executive who serves as Vice President of Engineering and Chief Technology Officer at NDI Medical, a Cleveland-based hybrid venture capital and commercialization firm founded in 2002 that focuses exclusively on neurodevice technologies. He is described by the firm as an expert in the design, development, testing, and manufacture of medical devices, including Class III active implantable medical devices (AIMDs), and has been instrumental in the design and commercial implementation of neurostimulation systems for more than 30 years.

Strother earned a bachelor's degree in electrical engineering from Case Western Reserve University in Cleveland and has held the State of Ohio's Professional Engineer (PE) certification since 1979. Much of his career has centered on the engineering disciplines that bring implantable neurostimulation devices to market — implementing quality systems and meeting quality-assurance, conformity-assessment, and regulatory requirements for medical devices.

Before NDI, Strother was a co-owner of Research Instrumentation Associates, Inc., an engineering firm that designed and manufactured ambulatory monitoring systems for large respiratory-product companies, and he later worked at a neurostimulation start-up (and at NeuroControl Corporation). His work sits within the broader Cleveland neurotechnology ecosystem closely tied to Case Western Reserve University. He is also associated with SPR Therapeutics — an NDI-related peripheral-nerve-stimulation company — where he has been listed as Chief Engineer.

• Invests through and alongside NDI Medical, which targets innovative neurodevice technologies addressing large unmet clinical needs (pain management, Parkinson's disease, depression, epilepsy, and stroke) in a market the firm sizes at more than $6 billion annually.
• Stage focus is seed and early-stage venture through commercialization, using NDI's "shared service model" — providing in-house engineering, IP portfolios, and proprietary platform technologies to move device concepts toward market and exit.
• As an engineer-investor, his diligence lens is technical and regulatory feasibility: device design, testing, manufacturability, and compliance for Class III active implantable medical devices.
• Sector is tightly specialized — neurostimulation hardware and systems (stimulators, leads, surgical tools, supporting software) rather than generalist healthcare or software.